No underlying genetic abnormality has been found in these patients, however most of them have early-onset SJIA, permanently high serum IL-1 and IL-18 levels, a poor response to biologics and more hypersensitivity reactions to tocilizumab. This evidence concerns the gene IL18 and systemic-onset juvenile idiopathic arthritis.